Dyne Therapeutics, Inc.
DYN
$25.70
-$0.26-1.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 20.93% | 17.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.01% | 7.88% | |||
| Operating Income | -45.01% | -7.88% | |||
| Income Before Tax | -47.75% | -7.95% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -47.75% | -7.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -47.75% | -7.95% | |||
| EBIT | -45.01% | -7.88% | |||
| EBITDA | -45.20% | -7.89% | |||
| EPS Basic | -47.37% | 3.44% | |||
| Normalized Basic EPS | -47.37% | 3.46% | |||
| EPS Diluted | -47.37% | 3.44% | |||
| Normalized Diluted EPS | -47.37% | 3.46% | |||
| Average Basic Shares Outstanding | 0.25% | 11.80% | |||
| Average Diluted Shares Outstanding | 0.25% | 11.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||